Due to its superiority compared with other chemotherapeutics in response and progression-free survival (PFS), erlotinib was further approved for the first-line therapy of patients with NSCLC with EGFR mutations [50]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.